Menarini / Stemline

Menarini, the private Italian pharmaceutical company based in Florence, commercialises the first oral SERD, elacestrant, through its Stemline oncology unit. Elacestrant, sold as Orserdu, is used in oestrogen-receptor-positive, HER2-negative breast cancer, and tagraxofusp, sold as Elzonris, treats blastic plasmacytoid dendritic cell neoplasm. OnCo links it to HR-positive, HER2-negative breast cancer and to BPDCN, and to both drug records. Whether the first oral SERD keeps its position as newer oral SERDs and degraders reach the market is the open question for Menarini's oncology business. Elacestrant has its own page.